Ringkasan AI
We reviewed 15 live results for trastuzumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Monoclonal Antibodies.
We reviewed 15 live results for trastuzumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Monoclonal Antibodies.
Sumber: Celltrion Healthcare
Deskripsi
Herzuma is a biosimilar trastuzumab, a monoclonal antibody designed as a targeted oncology therapy for HER2-positive early breast cancer, metastatic breast cancer, and advanced gastric cancer. It is supplied as a powder for concentrate for solution for infusion in 150mg and 440mg vials.
Paling cocok untuk
HER2-positive breast cancer, metastatic gastric cancer patients, cost-effective targeted therapy and oncology infusion treatment
Penilaian
Sumber: Pfizer Philippines Inc.
Deskripsi
Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022.
Paling cocok untuk
HER2-positive breast cancer, stomach cancer and targeted oncology therapy
Penilaian
Sumber: Biocon Biologics Philippines Inc.
Deskripsi
A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018.
Paling cocok untuk
HER2-positive breast cancer, gastric cancer treatment and oncology therapy
Penilaian
| Bandingkan | Herzuma (Trastuzumab) | Trazimera (Trastuzumab) | Trastuzumab Biosimilar |
|---|---|---|---|
| Sumber | Celltrion Healthcare | Pfizer Philippines Inc. | Biocon Biologics Philippines Inc. |
| Deskripsi | Herzuma is a biosimilar trastuzumab, a monoclonal antibody designed as a targeted oncology therapy for HER2-positive early breast cancer, metastatic breast cancer, and advanced gastric cancer. It is supplied as a powder for concentrate for solution for infusion in 150mg and 440mg vials. | Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022. | A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018. |
| Paling cocok untuk | HER2-positive breast cancer, metastatic gastric cancer patients, cost-effective targeted therapy and oncology infusion treatment | HER2-positive breast cancer, stomach cancer and targeted oncology therapy | HER2-positive breast cancer, gastric cancer treatment and oncology therapy |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"Herzuma (Trastuzumab) from Celltrion Healthcare."
Saya memilih ini karena Herzuma is an officially registered biosimilar in Singapore, providing a clinically equivalent and cost-effective alternative to the reference trastuzumab for HER2-targeted therapy.